Insilico Medicine advances AI drug for IPF to Phase III trials

Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into late-stage efficacy validation. IPF destroys respiratory capacity through severe lung tissue scarring. Patients […]

The post Insilico Medicine advances AI drug for IPF to Phase III trials appeared first on AI News.